Stock Performance and Market Context
On 21 September 2026, Parmax Pharma Ltd’s stock price closed at Rs.136.40, setting a new 52-week and all-time high. This price point represents a significant appreciation from its 52-week low of Rs.22.60, marking a substantial increase of 503.54%. The stock outperformed its sector by 0.35% on the day, registering a 1.00% gain compared to the Sensex’s 0.59% rise. Over the past week, the stock advanced by 1.98%, while the Sensex declined marginally by 0.06%. The one-month performance further emphasises the stock’s strength, with a 5.00% gain against the Sensex’s 3.62% fall.
Parmax Pharma’s longer-term performance is particularly noteworthy. Over three months, the stock surged by 96.60%, vastly outperforming the Sensex’s 2.69% decline. The one-year return stands at an impressive 314.34%, dwarfing the Sensex’s negative 9.55%. Year-to-date, the stock has appreciated by 303.19%, while the benchmark index has fallen by 12.30%. Even over a five-year horizon, Parmax Pharma’s 234.72% gain significantly exceeds the Sensex’s 26.66% rise, underscoring the company’s exceptional market journey despite its micro-cap status.
Technical Indicators and Trading Patterns
The stock’s technical profile supports the recent price strength. Parmax Pharma is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a broadly bullish trend. The overall technical trend is classified as mildly bullish, having shifted from a bullish stance on 16 September 2026 at a price of Rs.135.05.
Key technical indicators reinforce this positive momentum. Weekly and monthly MACD, Bollinger Bands, KST, and Dow Theory indicators are bullish, while the monthly RSI remains bearish, suggesting some caution in momentum strength. Immediate support is anchored at the 52-week low of Rs.22.60, with resistance levels previously encountered at Rs.127.74 (20-day moving average), Rs.76.58 (100-day moving average), and Rs.54.33 (200-day moving average). The stock’s current price surpasses all these resistance points, culminating in the new high of Rs.136.40.
Trading activity has shown some irregularities, with the stock not trading on four days out of the last twenty, and a notable delivery volume increase of 57.45% on the latest trading day compared to the five-day average. The one-month delivery volume has risen by 48.23%, indicating heightened investor participation in recent weeks.
Valuation Metrics and Financial Overview
Despite the strong price performance, Parmax Pharma remains a loss-making entity, with valuation multiples reflecting this status. The price-to-earnings ratio is not applicable due to losses, and the price-to-book value stands at a negative 15.11 times. Enterprise value multiples such as EV/EBITDA and EV/EBIT are also negative at -41.51 times and -27.60 times respectively, while EV/Sales is 5.64 times and EV/Capital Employed is 21.98 times.
The company does not currently pay dividends, with no dividend yield or payout recorded. The absence of dividend distribution aligns with the company’s financial profile and reinvestment strategy.
Quality and Financial Trends
Parmax Pharma’s overall quality grade is below average, reflecting challenges in long-term financial performance. Management risk, growth, and capital structure are all rated below average. The company has experienced a 5-year sales decline of 6.45% and a significant 213.12% decrease in EBIT over the same period. Average EBIT to interest coverage is weak at 0.66 times, although the company benefits from a net cash position with negative net debt and no promoter share pledging.
Return metrics are subdued, with an average return on capital employed (ROCE) of -28.89% and return on equity (ROE) of 5.12%. The tax ratio is 100%, and the dividend payout ratio remains at zero, consistent with the company’s current financial stance.
Short-term financial trends show positive developments. Net sales for the latest six months have grown by 70.31% to ₹11.53 crores, while profit after tax (PAT) increased to ₹1.62 crores. Quarterly profit before depreciation, interest, and tax (PBDIT) reached a high of ₹0.83 crores, and profit before tax excluding other income (PBT less OI) was ₹0.12 crores. Earnings per share (EPS) for the quarter hit a peak of ₹5.88. However, some caution is warranted as the debtors turnover ratio for the half-year is at a low 3.83 times, and non-operating income constitutes 94.55% of profit before tax, indicating reliance on non-core income sources.
Conclusion
Parmax Pharma Ltd’s ascent to an all-time high of Rs.136.40 on 21 September 2026 marks a significant milestone in its market journey. The stock’s exceptional performance over multiple time frames, combined with a broadly bullish technical outlook, highlights the company’s ability to generate substantial shareholder value despite its micro-cap classification and below-average quality metrics. While valuation multiples and financial fundamentals reflect ongoing challenges, the recent positive sales and profit trends underscore a noteworthy phase in the company’s evolution within the Pharmaceuticals & Biotechnology sector.
